SEARCH

SEARCH BY CITATION

References

  • 1
    Garcia Tsao G, Bosch J. Management of varices and variceal hemorrhage in cirrhosis. N Engl J Med 2010; 362: 823-832.
  • 2
    Garcia Tsao G, Lim J; Members of the Veterans Affairs Hepatitis C Resource Center Program. Management and treatment of patients with cirrhosis and portal hypertension: recommendations from the department of veterans affairs hepatitis C resource center program and the national hepatitis C program. Am J Gastroenterol 2009; 104: 1802-1829.
  • 3
    De Franchis R. Evolving consensus in portal hypertension. Report of the Baveno IV consensus workshop on methodology of diagnosis and therapy in portal hypertension. J Hepatol 2005; 43: 167-176.
  • 4
    Garcia-Tsao G, Sanyal AJ, Grace ND, Carey W; the Practice Guideline Committee of the American Association for the Study of Liver Diseases, the Practice Parameters Committee of the American College of Gastroenterology. Prevention and management of gastroesophageal varices and variceal hemorrhage in cirrhosis. HEPATOLOGY 2007; 46: 922-938.
  • 5
    Escorsell A, Bandi JC, Moitinho E, Feu F, García Pagán JC, Bosch J, et al. Time profiling of the haemodynamic effects of terlipressin in portal hypertension. J Hepatol 1997; 26: 621-627.
  • 6
    Merkel C, Gatta A, Bolognesi M, Finucci G, Bottaglia G, Angeli P, et al. Hemodynamic changes of systemic, hepatic and splenic circulation following triglycyl-lysin-vasopressin administration in alcoholic cirrhosis. Dig Dis Sci 1988; 33: 1103-1109.
  • 7
    Moller S, Hansen EF, Becker U, Brinch K, Henriksen JH, Bendtsen F. Central and systemic haemodynamic effects of terlipressin in portal hypertension patients. Liver 2000; 20: 51-59.
  • 8
    Machová A. Antidiuretic activity of terlipressin (triglycyl-lysine vasopressin) -- role of pressure natriuresis. Physiol Res 1992; 41: 121-127.
  • 9
    Krag A, Bendtsen F, Pedersen E, Holstein-Rathlou N, Moller S. Effects of terlipressin on the aquaretic system: evidence of antidiuretic effects. Am J Physiol Renal Physiol 2008; 295: F1295-F1300.
  • 10
    Escorsell A, Ruiz del Arbol L, Planas R, Albillos A, Bañares R, Calès P, et al. Multicenter randomized controlled trial of terlipressin versus sclerotherapy in the treatment of acute variceal bleeding: the TEST study. HEPATOLOGY 2000; 32: 471-476.
  • 11
    Feu F, Ruiz del Arbol L, Bañares R, Planas R, Bosch J, members of the variceal bleeding study group. Double-blind randomized controlled trial comparing terlipressin and somatostatin for acute variceal hemorrhage. Gastroenterology 1996; 111: 1291-1299.
  • 12
    Iannou GN, Doust J, Rockey DC. Systematic review: Terlipressin in acute oesophageal variceal haemorrhage. Aliment Pharmacol Ther 2003; 17: 53-64.
  • 13
    Bruha R, Marecek Z, Prochaza V, Lata J, Spicak J, Ehrmann J, et al. Double-blind randomized multicenter study comparing the efficacy and safety of 10-day to 5-day terlipressin treatment of bleeding esophageal varices. Hepatogastroenterology 2009; 56: 390-394.
  • 14
    Nazar A, Pereira GH, Guevara M, Martin-Llahi M, Pepin MN, Marinelli M, et al. Predictors of response to therapy with terlipressin and albumin in patients with cirrhosis and type 1 hepatorenal syndrome. HEPATOLOGY 2010; 51: 219-226.
  • 15
    Lo GH, Chen WC, Wang HM, Lin CK, Chan HH, Tsai WL, et al. Low-dose terlipressin plus banding ligation versus low-dose terlipressin alone in the prevention of very early rebleeding of oesophageal varices. Gut 2009; 58: 1275-1280.
  • 16
    Abid S, Jafri W, Hamid S, Salih M, Azam Z, Mumtaz K, et al. Terlipressin vs octreotide in bleeding esophageal varices as an adjuvant therapy with endoscopic band ligation: a randomized double-blind placebo-controlled trial. Am J Gastroenterol 2009; 104: 617-623.
  • 17
    Verbalis JG, Goldsmith SR, Greenberg A, Schrier R, Sterns R. Hyponatremia treatment guidelines 2007: expert panel recommendations. Am J Med 2007; 120: S1-S21.
  • 18
    Verbalis JG. The syndrome of innapropiate antidiuretic hormone secretion and other hypoosmolar disorders. In: SchrierRW. Diseases of the Kidney and Urinary Tract. Vol III. ed. 8. Philadelphia, PA: Lippincott Williams & Wilkins; 2007: 2214-2248.
  • 19
    Burcar PJ, Norenber MD, Yarnell PR. Hyponatremia and central pontine myelinolisis. Neurology 1997; 27: 223-226.
  • 20
    Laureno R, Karp BI. Pontine and extrapontine myelinolysis following rapid correction of hyponatremia. Lancet 1998; i: 1439-1441.
  • 21
    McNeill G, Halpenny D, Snow A, Geoghegan A, Torreggiani WC. Extrapontine myelinolysis after correction of hyponatremia presenting as generalised tonic seizures. Am J Emerg Med 2009; 27: 243.
  • 22
    Dunwoodie E, Jowett S. Terlipressin causing a hyponatremic seizure. Scand J Gastroenterol 2007; 42: 665.
  • 23
    Douriez E, Mollard P, Laval C, Albengres E, Laporte JP, Tillement JP. Severe hyponatremia after repeated administration of terlipressin [in French]. Therapie 1993; 48: 518-519.
  • 24
    Reddy P, Mooradian AD. Diagnosis and management of hyponatremia in hospitalised patients. Intern J Clin Practice 2009; 63: 1494-1508.
  • 25
    Ginès P, Guevara M. Hyponatremia in cirrosis: pathognesis, clinical significance, and management. HEPATOLOGY 2008; 48: 1002-1010.
  • 26
    Heuman DM, Abou-Assi SG, Habib A, Williams LM, Stravitz RT, Sanyal AJ, et al. Persistent ascites and low serum sodium identify patients with cirrhosis and low MELD scores who are at high risk for early death. HEPATOLOGY 2004; 40: 802-810.
  • 27
    Londoño MC, Guevara M, Rimola A, Navasa M, Taurà P, Mas A, et al. Hyponatremia impairs early posttransplantation outcome in patients with cirrhosis undergoing liver transplantation. Gastroenterology 2006; 130: 1135-1143.
  • 28
    Londoño MC, Cárdenas A, Guevara M, Quintó L, de Las Heras D, Navasa M, et al. MELD score and serum sodium in the prediction of survival of patients with cirrhosis awaiting liver transplantation. Gut 2007; 56: 1283-1290.
  • 29
    Ruf AE, Kremers WK, Chavez LL, Descalzi VI, Podesta LG, Villamil FG. Addition of serum sodium into the MELD scores predicts waiting list mortality better than MELD alone. Liver Transpl 2005; 11: 336-343.
  • 30
    Biggins SW, Rodriguez HJ, Bacchetti P, Bass NM, Roberts JP, Terrault NA. Serum sodium predicts mortality in patients listed for liver transplantation. HEPATOLOGY 2005; 41: 32-39.
  • 31
    Kim WR, Biggins SW, Kremers WWK, Wiesner RH, Kamath PS, Benson JT. Hyponatremia and mortality among patients on the liver transplantation waiting list. N Engl J Med 2008; 359: 1018-1026.